Day 18 - October 13, 2021

Before evidence resumed, defense counsel requested completion of the remaining juror inquiry, while the prosecution opposed delaying scheduled witnesses. The court noted that jurors already interviewed had affirmed their impartiality and directed that the six remaining jurors be questioned that morning in a continued sealed session. The available entry discloses no findings or dialogue. Counsel also agreed to limit anticipated testimony from Nimesh Jhaveri concerning the end of Theranos services at Walgreens and a negative Wall Street Journal article. Wade Miquelon testified about Walgreens's agreements, diligence, financial commitments, and rollout plans with Theranos. He said Walgreens understood that patient samples would be tested on Theranos's Edison device, but repeatedly described nationwide expansion as contingent on working technology and successful pilots. On cross-examination, he agreed that the model changed from rapid in-store testing to collection followed by testing at an offsite laboratory, and he explained that Johns Hopkins had relied on supplied information rather than independently operating an Edison. On redirect, Miquelon said his enthusiasm depended on assurances from Holmes and Ramesh Balwani that the technology worked and that most testing would use fingersticks. He recalled that an expected fingerstick rate of about 90 percent fell almost to zero for a period and said false representations about the technology would affect both the proposed service's value and Theranos's credibility. Roberto Amenta then described Fedwire operations and authenticated subpoenaed transfer records. The court admitted the records without objection, but failed juror displays interrupted their presentation, leaving his direct examination unfinished until the next morning.